VELCADE® (bortezomib) for Injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.
Your doctor may have recommended VELCADE to treat mantle cell lymphoma. This website offers resources that may help answer some of your questions, or those of your family or caregivers, about VELCADE therapy.
The information contained here is not intended to replace conversation with a healthcare professioinal. Always seek the advice of a qualified healthcare professional before starting any new treatment or with any questions you may have about a medical condition.
Please CLICK HERE to view important safety information.
For full Prescribing Information CLICK HERE.
For further information about VELCADE® (bortezomib) for Injection,
call 1-866-VELCADE (U.S. clinicians only). |
